These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 33488620)

  • 1. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow-derived mesenchymal stem cells inhibit CD8
    Liu Z; Mi F; Han M; Tian M; Deng L; Meng N; Luo J; Fu R
    Clin Exp Immunol; 2021 Jul; 205(1):53-62. PubMed ID: 33735518
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
    Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
    Mussetti A; Pellegrinelli A; Cieri N; Garzone G; Dominoni F; Cabras A; Montefusco V
    Ann Hematol; 2019 Jul; 98(7):1713-1720. PubMed ID: 31053880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass Cytometry Discovers Two Discrete Subsets of CD39
    Marsh-Wakefield F; Kruzins A; McGuire HM; Yang S; Bryant C; Fazekas de St Groth B; Nassif N; Byrne SN; Gibson J; Brown C; Larsen S; McCulloch D; Boyle R; Clark G; Joshua D; Ho PJ; Vuckovic S
    Front Immunol; 2019; 10():1596. PubMed ID: 31428081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 Blockade Reinvigorates Bone Marrow CD8
    Kwon M; Kim CG; Lee H; Cho H; Kim Y; Lee EC; Choi SJ; Park J; Seo IH; Bogen B; Song IC; Jo DY; Kim JS; Park SH; Choi I; Choi YS; Shin EC
    Clin Cancer Res; 2020 Apr; 26(7):1644-1655. PubMed ID: 31941832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
    Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.
    Vuckovic S; Bryant CE; Lau KHA; Yang S; Favaloro J; McGuire HM; Clark G; de St Groth BF; Marsh-Wakefield F; Nassif N; Abadir E; Vanguru V; McCulloch D; Brown C; Larsen S; Dunkley S; Khoo L; Gibson J; Boyle R; Joshua D; Ho PJ
    Blood Adv; 2020 Oct; 4(19):4593-4604. PubMed ID: 32986791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation between Morphological Typing and Monoclonality of Bone Marrow Plasma Cells and Its Diagnostic Value for High-Risk Smoldering Multiple Myeloma].
    Xiao HJ; Wang QJ; Wu S; Dai XB; Zhuang YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1146-1151. PubMed ID: 39192411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
    Damasceno D; Almeida J; Teodosio C; Sanoja-Flores L; Mayado A; Pérez-Pons A; Puig N; Arana P; Paiva B; Solano F; Romero A; Matarraz S; van den Bossche WBL; Flores-Montero J; Durie B; van Dongen JJM; Orfao A
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
    Kearl TJ; Jing W; Gershan JA; Johnson BD
    J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
    Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A
    Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.